<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613452</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-THLC 2022-03</org_study_id>
    <nct_id>NCT05613452</nct_id>
  </id_info>
  <brief_title>Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer</brief_title>
  <official_title>Prospective Phase II Clinical Study of Carbon Ion Beam Stereotactic Radiotherapy for Peripheral Type Early-stage Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of carbon ion therapy for stage Ia-IIa primary peripheral&#xD;
      non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS),&#xD;
      and the secondary endpoint was local control rate, overall survival (OS) and toxicities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2022</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease progression-free survival rate</measure>
    <time_frame>From date of radiotherapy started until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>disease progression-free survival rate was defined from the start of carbon ion radiotherapy till the date of disease progression at any site or death, or the last follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local control rate</measure>
    <time_frame>From date of radiotherapy started until the date of first documented local disease progression, assessed up to 100 months</time_frame>
    <description>local control rate was defined was defined from the start of carbon ion radiotherapy till the date of local failure or the last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>From date of radiotherapy started until the date of death from any cause, assessed up to 100 months</time_frame>
    <description>overall survival rate was defined from the start of carbon ion radiotherapy till the date of death or the last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-induced Adverse Events [Safety and Tolerability]</measure>
    <time_frame>From date of radiotherapy started, every 3-4 months within the first 2 years, every 6 months between years 3 and 5, and annually thereafter, assessed up to 100 months</time_frame>
    <description>Treatment-induced toxicities were scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, for events observed after the first dose of irradiation. Toxicities occurred 90 or more days after the completion of CIRT were defined as late toxicities.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received carbon ion radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon ion beam radiotherapy</intervention_name>
    <description>Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between the ages of 18 and 80.&#xD;
&#xD;
          2. ECOG general status score of 0-2 .&#xD;
&#xD;
          3. Primary non-small cell lung cancer (NSCLC) confirmed by histology or cytological&#xD;
             pathology, T1-2N0M0, stage Ia-IIa (AJCC/UICC 8th edition).&#xD;
&#xD;
          4. The location of the tumor belongs to the peripheral type defined in this study (2cm&#xD;
             and beyond (≥2cm) from the esophagus, main bronchial tree, spinal cord, heart, great&#xD;
             blood vessels, brachial plexus and stomach, and 1cm and beyond (≥1cm) from the chest&#xD;
             wall).&#xD;
&#xD;
          5. Medically inoperable, or patient refuses surgery.&#xD;
&#xD;
          6. Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x&#xD;
             109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1&gt;25%,&#xD;
             DLCO&gt;25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and&#xD;
             cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease&#xD;
             and other complications that may affect radiotherapy.4). Adequate liver function:&#xD;
             total bilirubin &lt;1.5 times the upper limit of normal value, and AST, ALT&lt;2 times the&#xD;
             upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times&#xD;
             the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary&#xD;
             protein &lt;2+. Patients with a baseline urinary protein level of 2+ or more should have&#xD;
             a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or&#xD;
             less.&#xD;
&#xD;
          7. Sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multiple primary tumors.&#xD;
&#xD;
          2. Patient fails to comply with the treatment protocol.&#xD;
&#xD;
          3. Complicated with other malignant tumors that have not been controlled.&#xD;
&#xD;
          4. Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage&#xD;
             and dose volume limitation requirements, or cannot meet the dose constrains of normal&#xD;
             tissue or organs.&#xD;
&#xD;
          5. Chest radiation therapy or radioactive particle implantation history.&#xD;
&#xD;
          6. Cardiac pacemakers or other internal metal prosthesis implants that may be affected by&#xD;
             high-energy radiation or may affect the dose distribution to the radiation target&#xD;
             area.&#xD;
&#xD;
          7. Pregnancy (confirmed by serum or urine β-HCG test) or lactation period.&#xD;
&#xD;
          8. HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy,&#xD;
             but because of concomitant disease cannot receive antiviral therapy. Active stage of&#xD;
             syphilis.&#xD;
&#xD;
          9. A history of mental illness may hinder the completion of treatment.&#xD;
&#xD;
         10. With serious comorbidity that may interfere with radiotherapy, including: (a) Acute&#xD;
             infectious diseases or acute active phase of chronic infection. b) Unstable angina&#xD;
             pectoris, congestive heart failure, myocardial infarction that has been hospitalized&#xD;
             in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or&#xD;
             other respiratory conditions requiring hospitalization. d) Severely impaired immune&#xD;
             function. e) Diseases with excessive sensitivity to radiation such as ataxia&#xD;
             telangiectasia. f) Other diseases that may affect particle radiotherapy.&#xD;
&#xD;
         11. Other circumstances that the physician considers inappropriate to participate in&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingfang Mao, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Li</last_name>
    <phone>86-21-38296678</phone>
    <email>jing.li@sphic.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201513</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Li</last_name>
      <phone>86-21-38296678</phone>
      <email>jing.li@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Kun Liu</last_name>
      <phone>86-21-38296678</phone>
      <email>kun.liu@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jingfang Mao, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai-liang Wu, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Jian Chen</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

